Experimental shot at stubborn blood cancers: LV009 injection enters early human trial
NCT ID NCT07330895
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test the safety of an experimental cell therapy called LV009 injection in 19 adults with relapsed or refractory CD19-positive blood cancers. Participants receive a single infusion, then are monitored for side effects and tumor response for up to 24 months. The study is not yet recruiting and is too small to prove effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LV009 injection (a type of cell therapy targeting CD19-positive blood cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat blood cancers that have come back or not responded to standard therapy.
- What could go wrong
- This is a very early, small study (19 people) focused on safety, not effectiveness. The treatment may cause serious side effects, and it is unknown if it will work at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19+ RELAPSE/REFRACTORY B-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.